Back to top
more

Guardant Health (GH)

(Delayed Data from NSDQ)

$21.40 USD

21.40
1,388,530

+0.79 (3.83%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $21.38 -0.02 (-0.09%) 7:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zacks.com featured highlights include: Activision Blizzard, Guardant Health, Vertex Pharmaceuticals, Aphria and Shopify

by Zacks Equity Research

Zacks.com featured highlights include: Activision Blizzard, Guardant Health, Vertex Pharmaceuticals, Aphria and Shopify

Sanghamitra Saha headshot

5 Top-Ranked Stocks to Tap Earnings Beat Potential

by Sanghamitra Saha

Forget earnings growth, bet on these top-ranked stocks to cash in on earnings beat.

Guardant Health (GH) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Guardant Health (GH) closed the most recent trading day at $65.84, moving +0.72% from the previous trading session.

Guardant Health (GH) in Focus: Stock Moves 6.5% Higher

by Zacks Equity Research

Guardant Health (GH) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Intercept (ICPT) Q4 Earnings Miss, Revenues Beat Estimates

by Zacks Equity Research

Intercept (ICPT) incurs wider loss in the fourth quarter while sales top mark. Shares fall probably as the action date for OCA's NDA to treat fibrosis due to NASH gets extended by the FDA.

Epizyme (EPZM) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Epizyme (EPZM) reports wider-than-expected loss in the fourth quarter of 2019. Nonetheless, its sales beat estimates.

Regeneron (REGN) Catches Eye: Stock Jumps 5.5%

by Zacks Equity Research

Regeneron (REGN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Zacks.com featured highlights include: Vista Outdoor, Guardant Health, Computer Programs and Systems, MicroStrategy and Sibanye Gold

by Zacks Equity Research

Zacks.com featured highlights include: Vista Outdoor, Guardant Health, Computer Programs and Systems, MicroStrategy and Sibanye Gold

Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of 10.00% and 15.42%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Nilanjan Banerjee headshot

5 Low-Beta Stocks to Keep You Calm Despite Market Volatility

by Nilanjan Banerjee

We have created a strategy which shows that securities involving low risk can also fetch impressive returns.

BioMarin (BMRN) Catches Eye: Stock Jumps 6.1%

by Zacks Equity Research

BioMarin (BMRN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Guardant Health (GH) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

During Guardant Health's (GH) Q4 earnings call, investors' focus will be on the updates related to Guardant360 test and the colorectal cancer screening rates of its LUNAR-2 blood test.

bluebird (BLUE) Q4 Earnings Miss Estimates, Revenues In Line

by Zacks Equity Research

bluebird (BLUE) reports a wider-than-expected loss and in-line revenues for the fourth quarter of 2019.

Kevin Cook headshot

Bull of the Day: Guardant Health (GH)

by Kevin Cook

Cancer diagnostics provider who delivered 181% revenue growth and 18,500 tests to patients and labs partners with Amgen

Alkermes' (ALKS) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

Alkermes (ALKS) beats earnings and sales estimates in the fourth quarter of 2019.

Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q4

by Zacks Equity Research

Ultragenyx (RARE) reports a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.

Trevena (TRVN) Resubmits NDA for Pain Drug Oliceridine to FDA

by Zacks Equity Research

Trevena (TRVN) resubmits the NDA to the FDA for IV oliceridine for the management of moderate-to-severe acute pain.

Benjamin Rains headshot

Should Growth Investors Buy this Cancer Screening Biotech Stock?

by Benjamin Rains

Exact Sciences is the biotech firm behind the popular at-home colon cancer screening test, Cologuard. So is EXAS stock worth considering for growth investors?

Has Guardant Health (GH) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (GH) Outperforming Other Medical Stocks This Year?

Alexion (ALXN) Q4 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Alexion (ALXN) beats on earnings and revenues in the fourth quarter of 2019.

Gilead's Mantle Cell Lymphoma Drug MAA Gets EMA Validation

by Zacks Equity Research

Gilead's (GILD) Marketing Authorization Application for KTE-X19 has been fully validated and is now under evaluation with the EMA.

Guardant Health (GH) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Guardant Health (GH) closed the most recent trading day at $80.04, moving -1.82% from the previous trading session.

Guardant Health (GH) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Guardant Health (GH) closed at $80.59, marking a +0.93% move from the previous day.

Jazz Enrolls First Patient in Phase II/III Leukemia Study

by Zacks Equity Research

Jazz (JAZZ) begins enrollment in the phase II/III study evaluating JZP-458 for treating pediatric and adult patients with acute lymphoblastic leukemia, hypersensitive to E. coli-derived asparaginases

Acceleron, Fulcrum Therapeutics Ink Deal for Pulmonary Disease

by Zacks Equity Research

Acceleron (XLRN) signs a collaboration/license pact with Fulcrum Therapeutics aimed at identifying small molecules designed to modulate specific pathways targeting a pulmonary disease indication.